Viatris Inc, a global healthcare player serving over 165 countries, reported a revenue decline of roughly 3% in fiscal 2025 to $14.3 billion, alongside a stark swing to a $2.66 billion operating loss driven primarily by portfolio divestitures and restructuring costs. The company is executing a strategic reset by shedding non-core businesses including biosimilars, women's healthcare, API, and OTC segments to streamline operations and prioritize debt reduction. Concurrently, Viatris advances its R&D pipeline with regulatory progress such as FDA acceptance for a presbyopia treatment, positioning for future growth. Despite resilient operating cash flow exceeding $2.3 billion and increased share buybacks, Viatris faces significant pricing pressure and regulatory risks typical of large pharma with complex manufacturing footprints.